HomeWhat is GSHArticlesFAQsGSH & DiseasesContact Us

 

 

 

 

home > articles > additional usages > evidence for oxidative stress in bronchiolitis obliterans syndrome after lung and heart-lung transplantation

Glutathione Articles - Additional Usages

Evidence for oxidative stress in bronchiolitis obliterans syndrome after lung and heart-lung transplantation
Behr, Juergen; Maier, Konrad; Braun, Barbara; Schwaiblmair, Martin; Vogelmeier, Claus
Transplantation: Volume 69(9)15 May 2000 pp 1856-1860

> download full text version as a PDF

ABSTRACT

Bronchiolitis obliterans syndrome (BOS) is the most serious long-term sequel of lung or heart-lung transplantation (H/LTX). Neutrophilia in the lower respiratory tract is a prominent feature of BOS. Because polymorphonuclear leukocytes (PMN) are capable of releasing large quantities of reactive oxygen species, we measured indicators of oxidative stress and glutathione levels representing antioxidant defense in H/LTX patients (HLTX, n=6; double-LTX, n=7; single-LTX, n=9). We analyzed 19 bronchoalveolar lavage (BAL) samples from 13 non-BOS patients (nine female, four male: age 39±4 years) and 17 BAL samples from nine BOS patients (five female, four male: age 33±2 years). PMN were the predominant BAL cell population in BOS (61.7±7.8% vs. 12.3±3.4%, P <0.001). Myeloperoxidase activity in the epithelial lining fluid and oxidized methionine residues in BAL-derived proteins were elevated in BOS (8.6±1.6 U/ml vs. 2.2±0.6 U/ml, P <0.01; and 12.6±1.1% vs. 7.7±0.8%, P <0.001, respectively). In addition, the concentration of reduced glutathione in epithelial lining fluid was decreased in BOS (162.6±20.1 􀈝M vs. 345.8±57.1 􀈝M, P <0.01), whereas the proportion of oxidized glutathione was increased (13.9±2.0% vs. 6.7±1.2%, P <0.001).
PMN, myeloperoxidase, and oxidized methionine residues were inversely correlated, whereas reduced glutathione was positively correlated with forced expiratory volume in 1 sec (P <0.05 to P <0.001). We conclude that excessive oxidative stress and a lack of glutathione are associated with BOS after H/LTX and may play relevant roles in the development of this disorder.

During the last decade, lung transplantation has gained widespread acceptance as a therapeutic option for a diverse array of advanced lung diseases. Although refinements of patient selection, operation procedure, immunosuppression, and posttransplantation care have led to an improvement of quality of life and survival, the 5-year actuarial survival after lung transplantation of 42.6% (1) is still unsatisfactory. A major obstacle for improved long-term survival rates is the development of bronchiolitis obliterans syndrome (BOS). BOS is the single most important cause of disablement and death in
long-term survivors of lung transplantation (1, 2). In patients who survive for 5 years, BOS is found in as much as 60-70% (2). The pathogenesis of BOS is as yet unclear. Chronic rejection is thought to be the underlying process, and acute rejection early after transplantation is believed to be the most important risk factor (2-5). However, augmentation of immunosuppression is only temporarily successful in some of the afflicted patients (3-5). In addition, infections like cytomegalovirus (CMV) infection may aggravate or initiate the development of BOS, underlining the need for antiinfectious
prophylaxis (4, 5).

Accumulation of polymorphonuclear leukocytes (PMN) in the lower respiratory tract has been reported to be a general feature of BOS, and infiltration of bronchial
epithelium by neutrophils has been observed (6, 7). Because PMN are capable of releasing, among other toxic factors, large amounts of reactive oxygen species (ROS), we hypothesized that oxidative stress, not adequately counterbalanced by antioxidants may contribute to the evolution of BOS after H/LTX. Therefore, we analyzed the oxidant/antioxidant balance in the lower respiratory tract of patients after lung and heart-lung transplantation with and without manifest BOS, as assessed by lung function criteria (8).

> download full text version as a PDF

     
 


Glutathione Experts | What is Glutathione (GSH)? | Glutathione Articles | GSH FAQs | GSH & Diseases | Contact